Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III PRM-151 in Idiopathic Pulmonary Fibrosis
2020-000791-38Phase 3Terminated
- Sponsor
- Roche
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing PRM-151 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Absolute change from baseline to Week 52 in forced vital capacity. Started Nov 2020; status: terminated.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2020-000791-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000791-38.